688578:SSEShanghai Allist Pharmaceuticals Co. Ltd. Class A Analysis

Shanghai Allist Pharmaceuticals trades around 85.5 CNY, well below its DCF-derived fair value of roughly 123 CNY, indicating a sizable upside. The stock’s PE of 15.95 is markedly lower than the biotechnology industry average of 24.2, reinforcing the undervaluation case. Revenue has surged 44% year‑over‑year and margins remain exceptionally high, with a gross margin of 96% and an operating margin above 45%. The balance sheet is robust, featuring ample cash of over 3.1 bn CNY and a negligible debt‑to‑equity ratio of 0.057. Dividend sustainability looks solid, given a low payout ratio of 15% and a consistent yield near 1.2%. However, technicals show a bearish price trend, with the market price sitting below the 20‑day, 50‑day, and 200‑day moving averages, and the RSI hovering around the neutral 47 level.
The MACD histogram is positive, suggesting a modest bullish momentum, while the price remains above the identified support at 78.8 CNY** and below resistance near 92.6 CNY. Volatility is elevated at over 31%** over the past month, yet beta is extremely low at 0.08**, limiting systematic risk. The combination of strong fundamentals, dividend safety, and a clear valuation gap outweighs the short‑term bearish technical bias, positioning the stock as an attractive opportunity for growth‑oriented investors.